Occam Recruits Board Director and SAB Member to In Vivo Cell Therapy Leader, Umoja Biopharma
.jpg)
In March 2026, Occam placed Athena Countouriotis, MD, on the Board of Directors of Umoja Biopharma and Andrew C. Chan, MD, PhD, on Umoja's Scientific Advisory Board.
Countouriotis is Co-Founder, President, and CEO of Avenzo Therapeutics and previously led Turning Point Therapeutics through its IPO and $4.1 billion acquisition by Bristol Myers Squibb in 2022. Her career spanssenior R&D and executive roles across Biotech and Pharma. She currently serves on the boards of BioMarin, Iovance Biotherapeutics, Passage Bio, and Recludix Pharma.
Chan is the former Senior Vice President of Research Biology at Genentech, where he led biological research across oncology, immunology, neuroscience, and infectious diseases for over two decades. His work on B-cell biology contributed to the development of ocrelizumab (Ocrevus®), the first approved therapy for both relapsing and progressive multiple sclerosis. He has authored more than 100 scientific publications and was named a Distinguished Fellow of the American Association of Immunologists in 2025.
About Umoja Biopharma
Umoja Biopharma, Inc. is a clinical-stage biotechnology company developing in vivo cell therapies to improve the reach, effectiveness, and access of CAR-T cell therapies in oncology and autoimmunity. The company closed an oversubscribed $100 million Series C financing in January 2025, co-led by Double Point Ventures and DCVC Bio, bringing total funds raised to over $370 million.
Occam Global is a leading executive search and advisory partner for entrepreneurs, investors, and corporations targeting exceptional goals across the life sciences, deep tech, and venture capital sectors worldwide. Since 2012, Occam has collaborated with top founders, CEOs, and investors across the tech industry to provide high-performing leaders who fuel growth. From stealth startups to public markets, we recruit senior executives, advise on organizational strategies, and invest alongside visionary teams to build innovative companies. Occam’s success is rooted in our proven ability to attract outstanding business and scientific leaders, seamless access to rare talent, and a strong commitment to results guided by high ethics and enlightened aggression. Whether you’re launching, leading, or investing, we are here to support growth through the power of talent.